Clinical trials focusing on BH3 mimetics (e.g., ABT737/199) in combination with standard breast cancer therapeutic drugs (e.g., tamoxifen) will undoubtedly promote the utilization and progression of the Bcl-2 apoptotic pathway in breast cancer treatment. The gene discussed is BCL2; the disease is breast cancer.